Edition:
United States

Amag Pharmaceuticals announces U.S. FDA filing acceptance


Thursday, 31 Aug 2017 08:00am EDT 

Aug 31 (Reuters) - Amag Pharmaceuticals Inc ::Amag announces U.S. FDA filing acceptance and six-month review of Feraheme® (Ferumoxytol) for the treatment of all adult patients with iron deficiency anemia.Amag Pharmaceuticals Inc - ‍prescription drug user fee act target action date of February 2, 2018 for feraheme​.